RD140 injection for multiple myeloma or plasma cell leukemia
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new therapy called RD140 for people with multiple myeloma or plasma cell leukemia that has come back or not responded after at least three prior treatments. It aims to see if this treatment can help when other options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75 years old
- Diagnosed with multiple myeloma or primary plasma cell leukemia that has returned or not responded to treatment
- Have had at least 3 previous treatments including a proteasome inhibitor, an immunomodulatory drug, and a CD38-targeted antibody
- Cancer has continued to grow during or within 12 months of the last treatment
- Able to care for yourself (ECOG score 0 or 1) and have adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that has come back or stopped responding to treatment. The goal is to see if this therapy can help control the cancer.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
This trial tests a new CAR-T cell therapy called LCAR-M61SQ for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It aims to see if this therapy can help control the disease.
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This study tests a new cell therapy called CT0596 for people with multiple myeloma or plasma cell leukemia that is not responding to standard treatments or has come back. The therapy uses your own immune cells that are modified to fight the cancer.
Hear when a new Relapsed/Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.